Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC

    • 07:00 - 09:00
    • 1/28/2021
    • Location: Scientific Program Auditorium
    • Not for CME Credit
    • Type: Workshop
    • Track: N.A.
    • +

      JICC01.02 - Chair

      07:00 - 07:00  |  Presenter: Tony S. Mok

      • Abstract

      No abstract available for this presentation

  • +

    IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges

    • 11:45 - 12:45
    • 1/28/2021
    • Location: Industry Symposia Auditorium (via Industry Hub)
    • Not for CME Credit
    • Type: Industry Symposium
    • Track:
    • +

      IS03.01 - Welcome and Introduction

      11:45 - 11:50  |  Presenter: Tony S. Mok

      • Abstract

      No abstract available for this presentation

    • +

      IS03.02 - Evolving Challenges for the Treatment of Advanced NSCLC

      11:50 - 12:00  |  Presenter: Tony S. Mok

      • Abstract

      No abstract available for this presentation

  • +

    FP14 - Targeted Therapy - Clinically Focused

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Targeted Therapy - Clinically Focused
    • +

      FP14.12 - Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.

      00:00 - 00:00  |  Presenter: Yi-long Wu

      • Abstract

      Loading...

  • +

    P03 - Early Stage/Localized Disease - Clinical Trials in Progress

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Early Stage/Localized Disease
    • +

      P03.05 - CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Jay M. Lee

      • Abstract

      Loading...

  • +

    P19 - Locoregional and Oligometastatic Disease - Oligometastatic Disease

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Locoregional and Oligometastatic Disease
    • +

      P19.01 - Local Ablative Radiotherapy on Oligo-Progression while Continued on EGFR-TKI in Advanced NSCLC Patients: A Longer Cohort

      00:00 - 00:00  |  Presenter: Florence Siu Ting Mok

      • Abstract

      Loading...

  • +

    P35 - Pathology - Genomics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • +

      P35.15 - Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Herbert H Loong

      • Abstract

      Loading...

  • +

    P76 - Targeted Therapy - Clinically Focused - EGFR

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050

      00:00 - 00:00  |  Presenter: Adam Pluzanski

      • Abstract

      Loading...

    • +

      P76.78 - Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study

      00:00 - 00:00  |  Presenter: Qing Zhou

      • Abstract

      Loading...

  • +

    IS15 - Industry Symposium Sponsored by Amoy: Lung Cancer Biomarker Panel Testing

    • 13:00 - 14:00
    • 1/31/2021
    • Location: Industry Symposia Auditorium (via Industry Hub)
    • Not for CME Credit
    • Type: Industry Symposium
    • Track:
    • +

      IS15.01 - Opening Remarks

      13:00 - 13:03  |  Presenter: Tony S. Mok

      • Abstract

      No abstract available for this presentation

    • +

      IS15.02 - Biomarker for Lung Cancer: Right Patient, Right Time, Right Test

      13:03 - 13:21  |  Presenter: Tony S. Mok

      • Abstract

      No abstract available for this presentation

    • +

      IS15.05 - Closing Remarks

      13:57 - 14:00  |  Presenter: Tony S. Mok

      • Abstract

      No abstract available for this presentation

  • +

    MA11 - Expanding Targetable Genetic Alterations in NSCLC

    • 14:15 - 15:15
    • 1/31/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      MA11.08 - Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC

      14:40 - 14:45  |  Presenter: Julien Mazieres

      • Abstract

      Loading...